Viatris Inc (VTRS) - Net Assets
Based on the latest financial reports, Viatris Inc (VTRS) has net assets worth $14.66 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($36.83 Billion) and total liabilities ($22.18 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Viatris Inc to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $14.66 Billion |
| % of Total Assets | 39.79% |
| Annual Growth Rate | 15.42% |
| 5-Year Change | -28.21% |
| 10-Year Change | 32.32% |
| Growth Volatility | 42.39 |
Viatris Inc - Net Assets Trend (1985–2025)
This chart illustrates how Viatris Inc's net assets have evolved over time, based on quarterly financial data. See Viatris Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Viatris Inc (1985–2025)
The table below shows the annual net assets of Viatris Inc from 1985 to 2025. For live valuation and market cap data, see VTRS market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $14.71 Billion | -21.06% |
| 2024-12-31 | $18.64 Billion | -8.95% |
| 2023-12-31 | $20.47 Billion | -2.87% |
| 2022-12-31 | $21.07 Billion | +2.83% |
| 2021-12-31 | $20.49 Billion | -10.72% |
| 2020-12-31 | $22.95 Billion | +93.15% |
| 2019-12-31 | $11.88 Billion | -2.33% |
| 2018-12-31 | $12.17 Billion | -8.57% |
| 2017-12-31 | $13.31 Billion | +19.70% |
| 2016-12-31 | $11.12 Billion | +13.84% |
| 2015-12-31 | $9.77 Billion | +198.10% |
| 2014-12-31 | $3.28 Billion | +10.68% |
| 2013-12-31 | $2.96 Billion | -11.80% |
| 2012-12-31 | $3.36 Billion | -4.25% |
| 2011-12-31 | $3.50 Billion | -3.06% |
| 2010-12-31 | $3.62 Billion | +14.95% |
| 2009-12-31 | $3.15 Billion | +12.86% |
| 2008-12-31 | $2.79 Billion | -18.93% |
| 2007-12-31 | $3.44 Billion | +103.17% |
| 2006-12-31 | $1.69 Billion | +114.82% |
| 2005-12-31 | $787.65 Million | -57.33% |
| 2004-12-31 | $1.85 Billion | +11.22% |
| 2003-12-31 | $1.66 Billion | +14.76% |
| 2002-12-31 | $1.45 Billion | +3.14% |
| 2001-12-31 | $1.40 Billion | +23.81% |
| 2000-12-31 | $1.13 Billion | -5.91% |
| 1999-12-31 | $1.20 Billion | +13.57% |
| 1998-12-31 | $1.06 Billion | +42.36% |
| 1997-12-31 | $744.50 Million | +12.85% |
| 1996-12-31 | $659.70 Million | +7.02% |
| 1995-12-31 | $616.40 Million | +27.70% |
| 1994-12-31 | $482.70 Million | +27.03% |
| 1993-12-31 | $380.00 Million | +28.38% |
| 1992-12-31 | $296.00 Million | +45.45% |
| 1991-12-31 | $203.50 Million | +32.75% |
| 1990-12-31 | $153.30 Million | +20.52% |
| 1989-12-31 | $127.20 Million | +21.96% |
| 1988-12-31 | $104.30 Million | +16.28% |
| 1987-12-31 | $89.70 Million | +31.91% |
| 1986-12-31 | $68.00 Million | +43.16% |
| 1985-12-31 | $47.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Viatris Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1184.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.50 Million | 0.08% |
| Other Comprehensive Income | $-2.71 Billion | -18.40% |
| Other Components | $17.79 Billion | 120.96% |
| Total Equity | $14.71 Billion | 100.00% |
Viatris Inc Competitors by Market Cap
The table below lists competitors of Viatris Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Telus Corp
TO:T
|
$18.68 Billion |
|
Alliant Energy Corp
NASDAQ:LNT
|
$18.69 Billion |
|
PERNOD RIC. SA SP.ADR 1/5
F:PER0
|
$18.69 Billion |
|
China Shenhua Energy Company Limited
F:IKF
|
$18.72 Billion |
|
Burlington Stores Inc
NYSE:BURL
|
$18.67 Billion |
|
Norsk Hydro ASA
F:NOHA
|
$18.67 Billion |
|
Pernod Ricard S.A.
PA:RI
|
$18.66 Billion |
|
Baoshan Iron & Steel Co Ltd
SHG:600019
|
$18.65 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Viatris Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 18,635,500,000 to 14,711,300,000, a change of -3,924,200,000 (-21.1%).
- Net loss of 3,514,900,000 reduced equity.
- Dividend payments of 561,200,000 reduced retained earnings.
- Share repurchases of 500,500,000 reduced equity.
- New share issuances of 2,600,000 increased equity.
- Other comprehensive income increased equity by 505,900,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.51 Billion | -23.89% |
| Dividends Paid | $561.20 Million | -3.81% |
| Share Repurchases | $500.50 Million | -3.4% |
| Share Issuances | $2.60 Million | +0.02% |
| Other Comprehensive Income | $505.90 Million | +3.44% |
| Other Changes | $143.90 Million | +0.98% |
| Total Change | $- | -21.06% |
Book Value vs Market Value Analysis
This analysis compares Viatris Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.28x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 82.69x to 1.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $0.19 | $16.04 | x |
| 1986-12-31 | $0.29 | $16.04 | x |
| 1987-12-31 | $0.36 | $16.04 | x |
| 1988-12-31 | $0.43 | $16.04 | x |
| 1989-12-31 | $0.52 | $16.04 | x |
| 1990-12-31 | $0.60 | $16.04 | x |
| 1991-12-31 | $0.79 | $16.04 | x |
| 1992-12-31 | $1.12 | $16.04 | x |
| 1993-12-31 | $1.41 | $16.04 | x |
| 1994-12-31 | $1.79 | $16.04 | x |
| 1995-12-31 | $2.29 | $16.04 | x |
| 1996-12-31 | $2.38 | $16.04 | x |
| 1997-12-31 | $2.69 | $16.04 | x |
| 1998-12-31 | $3.70 | $16.04 | x |
| 1999-12-31 | $4.11 | $16.04 | x |
| 2000-12-31 | $3.97 | $16.04 | x |
| 2001-12-31 | $4.89 | $16.04 | x |
| 2002-12-31 | $5.12 | $16.04 | x |
| 2003-12-31 | $6.01 | $16.04 | x |
| 2004-12-31 | $6.75 | $16.04 | x |
| 2005-12-31 | $3.36 | $16.04 | x |
| 2006-12-31 | $7.72 | $16.04 | x |
| 2007-12-31 | $13.24 | $16.04 | x |
| 2008-12-31 | $9.06 | $16.04 | x |
| 2009-12-31 | $10.20 | $16.04 | x |
| 2010-12-31 | $10.95 | $16.04 | x |
| 2011-12-31 | $7.96 | $16.04 | x |
| 2012-12-31 | $7.95 | $16.04 | x |
| 2013-12-31 | $7.46 | $16.04 | x |
| 2014-12-31 | $8.18 | $16.04 | x |
| 2015-12-31 | $19.63 | $16.04 | x |
| 2016-12-31 | $21.36 | $16.04 | x |
| 2017-12-31 | $24.80 | $16.04 | x |
| 2018-12-31 | $23.56 | $16.04 | x |
| 2019-12-31 | $23.01 | $16.04 | x |
| 2020-12-31 | $38.18 | $16.04 | x |
| 2021-12-31 | $16.95 | $16.04 | x |
| 2022-12-31 | $17.31 | $16.04 | x |
| 2023-12-31 | $16.96 | $16.04 | x |
| 2024-12-31 | $15.62 | $16.04 | x |
| 2025-12-31 | $12.57 | $16.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Viatris Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -24.58%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 2.53x
- Recent ROE (-23.89%) is below the historical average (11.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 43.58% | 25.62% | 1.44x | 1.18x | $15.95 Million |
| 1986 | 34.26% | 24.50% | 1.18x | 1.18x | $16.50 Million |
| 1987 | 28.09% | 26.25% | 0.88x | 1.21x | $16.23 Million |
| 1988 | 17.55% | 20.82% | 0.78x | 1.08x | $7.87 Million |
| 1989 | 20.60% | 27.46% | 0.69x | 1.08x | $13.48 Million |
| 1990 | 21.33% | 35.89% | 0.54x | 1.11x | $17.37 Million |
| 1991 | 19.71% | 30.40% | 0.58x | 1.11x | $19.75 Million |
| 1992 | 23.85% | 33.30% | 0.60x | 1.19x | $41.00 Million |
| 1993 | 19.24% | 29.03% | 0.62x | 1.06x | $35.10 Million |
| 1994 | 25.05% | 30.52% | 0.73x | 1.13x | $72.63 Million |
| 1995 | 16.60% | 26.04% | 0.57x | 1.12x | $40.66 Million |
| 1996 | 9.56% | 14.33% | 0.57x | 1.18x | $-2.87 Million |
| 1997 | 13.54% | 19.07% | 0.62x | 1.14x | $26.35 Million |
| 1998 | 10.89% | 16.00% | 0.60x | 1.14x | $9.41 Million |
| 1999 | 12.81% | 19.52% | 0.59x | 1.11x | $33.87 Million |
| 2000 | 3.28% | 4.39% | 0.58x | 1.29x | $-76.13 Million |
| 2001 | 18.56% | 23.57% | 0.68x | 1.15x | $120.03 Million |
| 2002 | 18.83% | 21.46% | 0.73x | 1.21x | $127.72 Million |
| 2003 | 20.16% | 24.34% | 0.73x | 1.14x | $168.63 Million |
| 2004 | 11.03% | 16.24% | 0.59x | 1.16x | $19.00 Million |
| 2005 | 23.43% | 14.68% | 0.67x | 2.37x | $105.78 Million |
| 2006 | 12.84% | 13.48% | 0.38x | 2.51x | $48.08 Million |
| 2007 | -44.58% | -52.23% | 0.26x | 3.34x | $-1.86 Billion |
| 2008 | -7.11% | -3.82% | 0.49x | 3.77x | $-471.85 Million |
| 2009 | 7.43% | 4.57% | 0.47x | 3.45x | $-80.54 Million |
| 2010 | 9.58% | 6.33% | 0.47x | 3.20x | $-15.07 Million |
| 2011 | 15.37% | 8.76% | 0.53x | 3.32x | $187.63 Million |
| 2012 | 19.18% | 9.43% | 0.57x | 3.57x | $306.78 Million |
| 2013 | 21.20% | 9.03% | 0.45x | 5.20x | $329.52 Million |
| 2014 | 28.55% | 12.04% | 0.49x | 4.86x | $603.81 Million |
| 2015 | 8.68% | 8.99% | 0.42x | 2.28x | $-128.84 Million |
| 2016 | 4.32% | 4.33% | 0.32x | 3.12x | $-631.62 Million |
| 2017 | 5.23% | 5.84% | 0.33x | 2.69x | $-634.76 Million |
| 2018 | 2.90% | 3.08% | 0.35x | 2.69x | $-864.21 Million |
| 2019 | 0.14% | 0.15% | 0.37x | 2.63x | $-1.17 Billion |
| 2020 | -2.92% | -5.61% | 0.19x | 2.68x | $-2.97 Billion |
| 2021 | -6.19% | -7.10% | 0.33x | 2.68x | $-3.32 Billion |
| 2022 | 9.86% | 12.78% | 0.33x | 2.37x | $-28.63 Million |
| 2023 | 0.27% | 0.35% | 0.32x | 2.33x | $-1.99 Billion |
| 2024 | -3.40% | -4.30% | 0.36x | 2.23x | $-2.50 Billion |
| 2025 | -23.89% | -24.58% | 0.38x | 2.53x | $-4.99 Billion |
Industry Comparison
This section compares Viatris Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $234,733,134
- Average return on equity (ROE) among peers: -29.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Viatris Inc (VTRS) | $14.66 Billion | 43.58% | 1.51x | $18.68 Billion |
| Aurora Cannabis Inc (ACB) | $1.68 Million | -10.54% | 0.00x | $177.38 Million |
| Akanda Corp (AKAN) | $4.28 Million | -95.78% | 0.85x | $7.56 Million |
| Akebia Ther (AKBA) | $68.12 Million | -199.28% | 3.41x | $263.59 Million |
| Alkermes Plc (ALKS) | $1.04 Billion | -15.16% | 0.88x | $7.35 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $1.64 Billion |
| Amphastar P (AMPH) | $448.72 Million | 0.31% | 0.41x | $854.96 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-186.87 Million | 0.00% | 0.00x | $5.18 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-186.87 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $263.49 Million | 12.07% | 0.07x | $190.27 Million |
| ANI Pharmaceuticals Inc (ANIP) | $457.60 Million | 4.10% | 0.98x | $1.80 Billion |
About Viatris Inc
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and … Read more